Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma

Journal of Oncology

Volumn , Issue , 2012, Pages

  Parenti, Gabriele ^a   Zampetti, Benedetta ^b   Rapizzi, Elena ^b,c   Ercolino, Tonino ^a   Giach, Valentino ^b   Mannelli, Massimo ^b,c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CYCLOPHOSPHAMIDE; DACARBAZINE; METADRENALIN; METOXYTYRAMINE; NORMETADRENALIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANATOMY; BIOCHEMISTRY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CLINICAL FEATURE; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; PARAGANGLIOMA; PATHOGENESIS; PHEOCHROMOCYTOMA; PROGNOSIS; REVIEW;

EID: 84864917821     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/872713     Document Type: Review

References (110)

1. Lenders J. W. M., Eisenhofer G., Mannelli M., Pacak K., Phaeochromocytoma Lancet 2005 366 9486 665 675 (Pubitemid 41176020)
2. Pacak K., Eisenhofer G., Ahlman H., Bornstein S. R., Gimenez-Roqueplo A. P., Grossman A. B., Kimura N., Mannelli M., McNicol A. M., Tischler A. S., Pheochromocytoma: recommendations for clinical practice from the First International Symposium Nature Clinical Practice Endocrinology and Metabolism 2007 3 2 92 102 (Pubitemid 46146962)
3. Welander J., Sderkvist P., Gimm O., Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas Endocrine-Related Cancer 2011 18 6 R253 R276
4. Chrisoulidou A., Kaltsas G., Ilias I., Grossman A. B., The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocrine-Related Cancer 2007 14 3 569 585 (Pubitemid 350074048)
5. Lee J. H., Barich F., Karnell L. H., Robinson R. A., Zhen W. K., Gantz B. J., Hoffman H. T., National cancer data base report on malignant paragangliomas of the head and neck Cancer 2002 94 3 730 737 (Pubitemid 34132302)
6. Mannelli M., Ianni L., Cilotti A., Conti A., Pheochromocytoma in Italy: a multicentric retrospective study European Journal of Endocrinology 1999 141 6 619 624 (Pubitemid 30064762)
7. Bravo E. L., Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma Endocrine Reviews 1994 15 3 356 368 (Pubitemid 24180793)
8. Erickson D., Kudva Y. C., Ebersold M. J., Thompson G. B., Grant C. S., Van Heerden J. A., Young W. F., Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients Journal of Clinical Endocrinology and Metabolism 2001 86 11 5210 5216 (Pubitemid 33070237)
9. Mannelli M., Lenders J. V. M., Pacak K., Subclinical pheochromocytoma. Best Practice Research Clinical Endocrinology Metabolism. In press
10. Lenders J. W. M., Pacak K., Walther M. M., Marston Linehan W., Mannelli M., Friberg P., Keiser H. R., Goldstein D. S., Eisenhofer G., Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association 2002 287 11 1427 1434 (Pubitemid 34250506)
11. Grossman A., Pacak K., Sawka A., Lenders J. W. M., Harlander D., Peaston R. T., Reznek R., Sisson J., Eisenhofer G., Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Annals of the New York Academy of Sciences 2006 1073 332 347 (Pubitemid 44912029)
12. Davidson F. D., Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines Annals of Clinical Biochemistry 2002 39 6 557 566 (Pubitemid 35316288)
13. Eisenhofer G., Keiser H., Friberg P., Mezey E., Huynh T. T., Hiremagalur B., Ellingson T., Duddempudi S., Eijsbouts A., Lenders J. W. M., Plasma metanephrines are markers of pheochromocytoma produced by catechol-O- methyltransferase within tumors Journal of Clinical Endocrinology and Metabolism 1998 83 6 2175 2185 (Pubitemid 28496356)
14. Rao F., Keiser H. R., O'Connor D. T., Malignant pheochromocytoma: chromaffin granule transmitters and response to treatment Hypertension 2000 36 6 1045 1052
15. Brouwers F. M., Eisenhofer G., Tao J. J., Kant J. A., Adams K. T., Linehan W. M., Pacak K., High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing Journal of Clinical Endocrinology and Metabolism 2006 91 11 4505 4509 (Pubitemid 44833431)
16. van der Harst E., de Herder W. W., de Krijger R. R., Bruining H. A., Bonjer H. J., Lamberts S. W. J., van den Meiracker A. H., Stijnen T. H., Boomsma F., The value of plasma markers for the clinical behaviour of phaeochromocytomas European Journal of Endocrinology 2002 147 1 85 94 (Pubitemid 34814744)
17. Guignat L., Bidart J. M., Nocera M., Comoy E., Schlumberger M., Baudin E., Chromogranin A and the -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma British Journal of Cancer 2001 84 6 808 812 (Pubitemid 32275655)
18. Algeciras-Schimnich A., Preissner C. M., Young W. F., Singh R. J., Grebe S. K. G., Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma Journal of Clinical Endocrinology and Metabolism 2008 93 1 91 95
19. Moreno A. M., Castilla-Guerra L., Martnez-Torres M. C., Torres-Olivera F., Fernndez E., Galera-Davidson H., Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas Neuropeptides 1999 33 2 159 163 (Pubitemid 29254079)
20. Oishi S., Sato T., Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma Cancer 1988 61 6 1167 1170 (Pubitemid 18078607)
21. Guillemot J., Barbier L., Thouennon E., Vallet-Erdtmann V., Montero-Hadjadje M., Lefebvre H., Klein M., Muresan M., Plouin P. F., Seidah N., Vaudry H., Anouar Y., Yon L., Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas Annals of the New York Academy of Sciences 2006 1073 527 532 (Pubitemid 44912047)
22. Ilias I., Pacak K., Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma Journal of Clinical Endocrinology and Metabolism 2004 89 2 479 491 (Pubitemid 38269845)
23. Mannelli M., Colagrande S., Valeri A., Parenti G., Incidental and metastatic adrenal masses Seminars in Oncology 2010 37 6 649 661
24. Blake M. A., Kalra M. K., Maher M. M., Sahani D. V., Sweeney A. T., Mueller P. R., Hahn P. F., Boland G. W., Pheochromocytoma: an imaging chameleon Radiographics 2004 24 S87 S99
25. Shulkin B. L., Ilias I., Sisson J. C., Pacak K., Current trends in functional imaging of pheochromocytomas and paragangliomas Annals of the New York Academy of Sciences 2006 1073 374 382 (Pubitemid 44912032)
26. Dubois L. A., Gray D. K., Dopamine-secreting pheochromocytomas: in search of a syndrome World Journal of Surgery 2005 29 7 909 913 (Pubitemid 41800727)
27. Telischi F. F., Bustillo R., Whiteman M. L. H., Serafini A. N., Reisberg M. J., Gomez-Marin O., Civantos F. J., Balkany T. J., Octreotide scintigraphy for the detection of paragangliomas Otolaryngology, Head and Neck Surgery 2000 122 3 358 362 (Pubitemid 30155313)
28. Buchmann I., Henze M., Engelbrecht S., Eisenhut M., Runz A., Schfer M., Schilling T., Haufe S., Herrmann T., Haberkorn U., Comparison of 68 Ga-DOTATOC PET and 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging 2007 34 10 1617 1626 (Pubitemid 47476920)
29. Hofmann M., Maecke H., Brner A. R., Weckesser E., Schffski P., Oei M. L., Schumacher J., Henze M., Heppeler A., Meyer G. J., Knapp W. H., Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data European Journal of Nuclear Medicine 2001 28 12 1751 1757
30. Kowalski J., Henze M., Schuhmacher J., Mcke H. R., Hofmann M., Haberkorn U., Evaluation of positron emission tomography imaging using [ 68 Ga]-DOTA-D Phe1-Tyr3- octreotidein comparison to [ 111 In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Molecular Imaging and Biology 2003 5 1 42 48 (Pubitemid 36596544)
31. Ilias I., Yu J., Carrasquillo J. A., Chen C. C., Eisenhofer G., Whatley M., McElroy B., Pacak K., Superiority of 6-[ 18 F]-fluorodopamine positron emission tomography versus [ 131 I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma Journal of Clinical Endocrinology and Metabolism 2003 88 9 4083 4087 (Pubitemid 37153702)
32. Hoegerle S., Nitzsche E., Altehoefer C., Ghanem N., Manz T., Brink I., Reincke M., Moser E., Neumann H. P. H., Pheochromocytomas: detection with 18 F-DOPA whole-body PET-initial results Radiology 2002 222 2 507 512 (Pubitemid 34106126)
33. Timmers H. J. L. M., Kozupa A., Chen C. C., Carrasquillo J. A., Ling A., Eisenhofer G., Adams K. T., Solis D., Lenders J. W. M., Pacak K., Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma Journal of Clinical Oncology 2007 25 16 2262 2269 (Pubitemid 46954653)
34. Mamede M., Carrasquillo J. A., Chen C. C., Del Corral P., Whatley M., Ilias I., Ayala A., Pacak K., Discordant localization of 2-[ 18 F]-fluoro-2-deoxy-D-glucose in 6-[ 18 F]-fluorodopamine- and [ 123 I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites Nuclear Medicine Communications 2006 27 1 31 36 (Pubitemid 44391837)
35. Trampal C., Engler H., Juhlin C., Bergstrm M., Lngstrm B., Pheochromocytomas: detection with 11 C Hydroxyephedrine PET Radiology 2004 230 2 423 428
36. Linnoila R. I., Keiser H. R., Steinberg S. M., Lack E. E., Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features Human Pathology 1990 21 11 1168 1180 (Pubitemid 20382001)
37. Kimura N., Watanabe T., Noshiro T., Shizawa S., Miura Y., Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors Endocrine Pathology 2005 16 1 23 32 (Pubitemid 41278311)
38. Thompson L. D. R., Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases American Journal of Surgical Pathology 2002 26 5 551 566 (Pubitemid 34438716)
39. Strong V. E., Kennedy T., Al-Ahmadie H., Tang L., Coleman J., Fong Y., Brennan M., Ghossein R. A., Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis Surgery 2008 143 6 759 768
40. Boltze C., Mundschenk J., Unger N., Schneider-Stock R., Peters B., Mawrin C., Hoang-Vu C., Roessner A., Lehnert H., Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma Journal of Clinical Endocrinology and Metabolism 2003 88 9 4280 4286 (Pubitemid 37153732)
41. Liu T. H., Chen Y. J., Wu S. F., Gao J., Jiang W. J., Lu Z. H., Guan J., Wei S. Z., Luo Y. F., Cao J. L., Wan J. W., Distinction between benign and malignant pheochromocytomas Zhonghua Bing Li Xue Za Zhi 2004 33 3 198 202
42. Hyry V., Salmenkivi K., Arola J., Heikkil P., Haglund C., Sariola H., High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma Endocrine-Related Cancer 2009 16 4 1211 1218
43. Waldmann J., Slater E. P., Langer P., Buchholz M., Ramaswamy A., Walz M. K., Schmid K. W., Feldmann G., Bartsch D. K., Fendrich V., Expression of the transcription factor Snail and its target gene Twist are associated with malignancy in pheochromocytomas Annals of Surgical Oncology 2009 16 7 1997 2005
44. Engels B. M., Hutvagner G., Principles and effects of microRNA-mediated post-transcriptional gene regulation Oncogene 2006 25 46 6163 6169 (Pubitemid 44527846)
45. Meyer-Rochow G. Y., Jackson N. E., Conaglen J. V., Whittle D. E., Kunnimalaiyaan M., Chen H., Westin G., Sandgren J., Stlberg P., Khanafshar E., Shibru D., Duh Q. Y., Clark O. H., Kebebew E., Gill A. J., Clifton-Bligh R., Robinson B. G., Benn D. E., Sidhu S. B., MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets Endocrine-Related Cancer 2010 17 3 835 846
46. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Ming Hui Wei, Chen F., Glenn G., Choyke P., Walther M. M., Weng Y., Identification of the von Hippel-Lindau disease tumor suppressor gene Science 1993 260 5112 1317 1320 (Pubitemid 23231974)
47. Walther M. M., Reiter R., Keiser H. R., Choyke P. L., Venzon D., Hurley K., Gnarra J. R., Reynolds J. C., Glenn G. M., Zbar B., Linehan W. M., Clinical and genetic characterization of pheochromocytoma in von Hippel- Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma Journal of Urology 1999 162 3 I 659 664 (Pubitemid 29436843)
48. Neumann H. P. H., Berger D. P., Sigmund G., Blum U., Schmidt D., Parmer R. J., Volk B., Kirste G., Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel- Lindau disease New England Journal of Medicine 1993 329 21 1531 1538 (Pubitemid 23332438)
49. Neumann H. P. H., Berger D. P., Sigmund G., Blum U., Schmidt D., Parmer R. J., Volk B., Kirste G., Erratum: pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease New England Journal of Medicine 1994 331 22 1535
50. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F. W., Jackson C. E., Tunnacliffe A., Ponder B. A. J., Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours Human Molecular Genetics 1994 3 2 237 241 (Pubitemid 24060936)
51. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F. W., Jackson C. E., Tunnacliffe A., Ponder B. A. J., Erratum: point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours Human Molecular Genetics 1994 3 4 686 (Pubitemid 24122207)
52. Eng C., Seminars in medicine of the Beth Israel Hospital, Boston: the RET proto- oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease New England Journal of Medicine 1996 335 13 943 951 (Pubitemid 26314449)
53. White R., O'Connell P., Identification and characterization of the gene for neurofibromatosis type 1 Current Opinion in Genetics and Development 1991 1 1 15 19 (Pubitemid 121002291)
54. Neumann H. P. H., Bausch B., McWhinney S. R., Bender B. U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., Smith W. M., Munk R., Manz T., Glaesker S., Apel T. W., Treier M., Reineke M., Walz M. K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M., Pezkowska M., Szmigielski C., Eng C., Germ-line mutations in nonsyndromic pheochromocytoma New England Journal of Medicine 2002 346 19 1459 1466 (Pubitemid 34755714)
55. Baysal B. E., Ferrell R. E., Willett-Brozick J. E., Lawrence E. C., Myssiorek D., Bosch A., Van Der Mey A., Taschner P. E. M., Rubinstein W. S., Myers E. N., Richard C. W., Cornelisse C. J., Devilee P., Devlin B., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 2000 287 5454 848 851 (Pubitemid 30084326)
56. Niemann S., Muller U., Mutations in SDHC cause autosomal dominant paraganglioma, type 3 Nature Genetics 2000 26 3 268 270
57. Astuti D., Latif F., Dallol A., Dahia P. L. M., Douglas F., George E., Skldberg F., Husebye E. S., Eng C., Maher E. R., Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma American Journal of Human Genetics 2001 69 1 49 54 (Pubitemid 32614017)
58. Burnichon N., Brire J. J., Libé R., Vescovo L., Rivire J., Tissier F., Jouanno E., Jeunemaitre X., Bénit P., Tzagoloff A., Rustin P., Bertherat J., Favier J., Gimenez-Roqueplo A. P., SDHA is a tumor suppressor gene causing paraganglioma Human Molecular Genetics 2010 19 15 3011 3020
59. Hao H. X., Khalimonchuk O., Schraders M., Dephoure N., Bayley J. P., Kunst H., Devilee P., Cremers C. W. R. J., Schiffman J. D., Bentz B. G., Gygi S. P., Winge D. R., Kremer H., Rutter J., SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 2009 325 5944 1139 1142
60. Qin Y., Yao L., King E. E., Buddavarapu K., Lenci R. E., Chocron E. S., Lechleiter J. D., Sass M., Aronin N., Schiavi F., Boaretto F., Opocher G., Toledo R. A., Toledo S. P. A., Stiles C., Aguiar R. C. T., Dahia P. L. M., Germline mutations in TMEM127 confer susceptibility to pheochromocytoma Nature Genetics 2010 42 3 229 233
61. Comino-Méndez I., Gracia-Aznrez F. J., Schiavi F., Landa I., Leandro-Garca L. J., Letn R., Honrado E., Ramos-Medina R., Caronia D., Pita G., Gmez-Graa., De Cubas A. A., Inglada-Pérez L., Maliszewska A., Taschin E., Bobisse S., Pica G., Loli P., Hernndez-Lavado R., Daz J. A., Gmez-Morales M., Gonzlez-Neira A., Roncador G., Rodrguez-Antona C., Bentez J., Mannelli M., Opocher G., Robledo M., Cascn A., Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma Nature Genetics 2011 43 7 663 667
62. Gimenez-Roqueplo A. P., Favier J., Rustin P., Rieubland C., Crespin M., Nau V., Van Kien P. K., Corvol P., Plouin P. F., Jeunemaitre X., Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas Cancer Research 2003 63 17 5615 5621 (Pubitemid 37139886)
63. Mannelli M., Castellano M., Schiavi F., Filetti S., Giacch M., Mori L., Pignataro V., Bernini G., Giach V., Bacca A., Biondi B., Corona G., Di Trapani G., Grossrubatscher E., Reimondo G., Arnaldi G., Giacchetti G., Veglio F., Loli P., Colao A., Ambrosio M. R., Terzolo M., Letizia C., Ercolino T., Opocher G., Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas Journal of Clinical Endocrinology and Metabolism 2009 94 5 1541 1547
64. Dahia P. L. M., Ross K. N., Wright M. E., Hayashida C. Y., Santagata S., Barontini M., Kung A. L., Sanso G., Powers J. F., Tischler A. S., Hodin R., Heitritter S., Moore Jr. F., Dluhy R., Sosa J. A., Ocal I. T., Benn D. E., Marsh D. J., Robinson B. G., Schneider K., Garber J., Arum S. M., Korbonits M., Grossman A., Pigny P., Toledo S. P. A., Nose V., Li C., Stiles C. D., A HIf1 regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas PLoS Genetics 2005 1 1 72 80
65. Favier J., Brire J. J., Burnichon N., Rivire J., Vescovo L., Benit P., Giscos-Douriez I., De Reynis A., Bertherat J., Badoual C., Tissier F., Amar L., Libé R., Plouin P. F., Jeunemaitre X., Rustin P., Gimenez-Roqueplo A. P., The Warburg effect is genetically determined in inherited pheochromocytomas PLoS One 2009 4 9
66. Califano D., Rizzo C., D'Alessio A., Colucci-D'Amato G. L., Cali G., Cannada Bartoli P., Santelli G., Vecchio G., De Franciscis V., Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells Journal of Biological Chemistry 2000 275 25 19297 19305 (Pubitemid 30422903)
67. Martin G. A., Viskochil D., Bollag G., McCabe P. C., Crosier W. J., Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R. M., Innis M. A., McCormick F., The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 Cell 1990 63 4 843 849 (Pubitemid 120035057)
68. Johannessen C. M., Reczek E. E., James M. F., Brems H., Legius E., Cichowski K., The NF1 tumor suppressor critically regulates TSC2 and mTOR Proceedings of the National Academy of Sciences of the United States of America 2005 102 24 8573 8578 (Pubitemid 40862777)
69. Johannessen C. M., Johnson B. W., Williams S. G., Chan A. W., Reczek E. E., Lynch R. C., Rioth M. J., McClatchey A., Ryeom S., Cichowski K., TORC1 Is Essential for NF1-Associated Malignancies Current Biology 2008 18 1 56 62
70. Brauckhoff M., Gimm O., Dralle H., Preoperative and surgical therapy in sporadic and familial phaeochromocytoma. H. Lehnert Eds.: Phaeochromocytoma, Pathophysiology and Clinical Management Frontiers of Hormone Research 2004 31 121 144
71. Buhl T., Mortensen J., Kjaer A., I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma a case report Clinical Nuclear Medicine 2002 27 3 183 185 (Pubitemid 34195230)
72. Maithel S. K., Fong Y., Hepatic ablation for neuroendocrine tumor metastases Journal of Surgical Oncology 2009 100 8 635 638
73. Sisson J. C., Shapiro B., Beierwaltes W. H., Radiopharmaceutical treatment of malignant pheochromocytoma Journal of Nuclear Medicine 1984 25 2 197 206 (Pubitemid 14187477)
74. Kaltsas G. A., Mukherjee J. J., Foley R., Britton K. E., Grossman A. B., Treatment of metastatic pheochromocytoma and paraganglioma with 131 I-meta-iodobenzylguanidine (MIBG) Endocrinologist 2003 13 4 321 333 (Pubitemid 36944539)
75. Kaltsas G. A., Papadogias D., Makras P., Grossman A. B., Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocrine-Related Cancer 2005 12 4 683 699 (Pubitemid 41815771)
76. Fitzgerald P. A., Goldsby R. E., Huberty J. P., Price D. C., Hawkins R. A., Veatch J. J., Dela Cruz F., Jahan T. M., Linker C. A., Damon L., Matthay K. K., Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) Annals of the New York Academy of Sciences 2006 1073 465 470 (Pubitemid 44912041)
77. Loh K. C., Fitzgerald P. A., Matthay K. K., Yeo P. P. B., Price D. C., The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131 I-MIBG): a comprehensive review of 116 reported patients Journal of Endocrinological Investigation 1997 20 11 648 658 (Pubitemid 28056835)
78. Kwekkeboom D. J., Mueller-Brand J., Paganelli G., Anthony L. B., Pauwels S., Kvols L. K., O'Dorisio T. M., Valkema R., Bodei L., Chinol M., Maecke H. R., Krenning E. P., Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs Journal of Nuclear Medicine 2005 46 1 S62 S66
79. Kwekkeboom D. J., De Herder W. W., Kam B. L., Van Eijck C. H., Van Essen M., Kooij P. P., Feelders R. A., Van Aken M. O., Krenning E. P., Treatment with the radiolabeled somatostatin analog [ 177 Lu- DOTA 0,Tyr 3 ]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology 2008 26 13 2124 2130
80. Forrer F., Riedweg I., Maecke H. R., Mueller-Brand J., Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma Quarterly Journal of Nuclear Medicine and Molecular Imaging 2008 52 4 334 340
81. Teno S., Tanabe A., Nomura K., Demura H., Acutely exacerbated hypertension and increased inflammatory signs due to radiation treatment for metastatic pheochromocytoma Endocrine Journal 1996 43 5 511 516 (Pubitemid 26386558)
82. Andersen K. F., Altaf R., Krarup-Hansen A., Kromann-Andersen B., Horn T., Christensen N. J., Hendel H. W., Malignant pheochromocytomas and paragangliomasthe importance of a multidisciplinary approach Cancer Treatment Reviews 2011 37 2 111 119
83. Averbuch S. D., Steakley C. S., Young R. C., Gelmann E. P., Goldstein D. S., Stull R., Keiser H. R., Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine Annals of Internal Medicine 1988 109 4 267 273
84. Huang H., Abraham J., Hung E., Averbuch S., Merino M., Steinberg S. M., Pacak K., Fojo T., Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients Cancer 2008 113 8 2020 2028
85. Nakane M., Takahashi S., Sekine I., Fukui I., Koizumi M., Kage K., Ito Y., Aiba K., Horikoshi N., Hatake K., Ishikawa Y., Ogata E., Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline Annals of Oncology 2003 14 9 1449 1451
86. Grogan R. H., Mitmaker E. J., Duh Q. Y., Changing paradigms in the treatment of malignant pheochromocytoma Cancer Control 2011 18 2 104 112
87. Banerji U., Heat shock protein 90 as a drug target: some like it hot Clinical Cancer Research 2009 15 1 9 14
88. Powers M. V., Workman P., Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocrine-Related Cancer 2006 13 1 S125 S135
89. Semenza G. L., Evaluation of HIF-1 inhibitors as anticancer agents Drug Discovery Today 2007 12 19-20 853 859 (Pubitemid 47554628)
90. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., Powis G., Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 Molecular Cancer Therapeutics 2004 3 3 233 244 (Pubitemid 39193698)
91. Welsh S. J., Williams R. R., Birmingham A., Newman D. J., Kirkpatrick D. L., Powis G., The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation Molecular cancer therapeutics 2003 2 3 235 243
92. Yao J. C., Phan A. T., Chang D. Z., Wolff R. A., Hess K., Gupta S., Jacobs C., Mares J. E., Landgraf A. N., Rashid A., Meric-Bernstam F., Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study Journal of Clinical Oncology 2008 26 26 4311 4318
93. Druce M. R., Kaltsas G. A., Fraenkel M., Gross D. J., Grossman A. B., Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) Hormone and Metabolic Research 2009 41 9 697 702
94. Nlting S., Grossman A. B., Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies Endocrine Pathology 2012 23 1 21 33
95. Boltze C., Lehnert H., Schneider-Stock R., Peters B., Hoang-Vu C., Roessner A., HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma Endocrine 2003 22 3 193 201 (Pubitemid 38183695)
96. Salmenkivi K., Heikkil P., Liu J., Haglund C., Arola J., VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome APMIS 2003 111 4 458 464 (Pubitemid 36735003)
97. Zielke A., Middeke M., Hoffmann S., Colombo-Benkmann M., Barth P., Hassan I., Wunderlich A., Hofbauer L. C., Duh Q. Y., Hamberger B., Nwariaku F., Frilling A., Carter W. B., Mitchell B., Pasieka J. L., VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors Surgery 2002 132 6 1056 1063 (Pubitemid 36026955)
98. Favier J., Plouin P. F., Corvol P., Gasc J. M., Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors American Journal of Pathology 2002 161 4 1235 1246
99. Kolomecki K., Stepien H., Bartos M., Kuzdak K., Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours Endocrine Regulations 2001 35 1 9 16 (Pubitemid 33711948)
100. Takekoshi K., Isobe K., Yashiro T., Hara H., Ishii K., Kawakami Y., Nakai T., Okuda Y., Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas Life Sciences 2004 74 7 863 871 (Pubitemid 37501135)
101. Jimenez C., Cabanillas M. E., Santarpia L., Jonasch E., Kyle K. L., Lano E. A., Matin S. F., Nunez R. F., Perrier N. D., Phan A., Rich T. A., Shah B., Williams M. D., Waguespack S. G., Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors Journal of Clinical Endocrinology and Metabolism 2009 94 2 386 391
102. Joshua A. M., Ezzat S., Asa S. L., Evans A., Broom R., Freeman M., Knox J. J., Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma Journal of Clinical Endocrinology and Metabolism 2009 94 1 5 9
103. Park K. S., Lee J. L., Ahn H., Koh J. M., Park I., Choi J. S., Kim Y. R., Park T. S., Ahn J. H., Lee D. H., Kim T. W., Lee J. S., Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma Japanese Journal of Clinical Oncology 2009 39 5 327 331
104. Hahn N. M., Reckova M., Cheng L., Baldridge L. A., Cummings O. W., Sweeney C. J., Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate Journal of Clinical Oncology 2009 27 3 460 463
105. Gross D. J., Munter G., Bitan M., Siegal T., Gabizon A., Weitzen R., Merimsky O., Ackerstein A., Salmon A., Sella A., Slavin S., The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R Endocrine-Related Cancer 2006 13 2 535 540 (Pubitemid 43886675)
106. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J., Barlogie B., Siegel D., Crowley J., Antitumor activity of thalidomide in refractory multiple myeloma New England Journal of Medicine 1999 341 21 1565 1571
107. Sparano J. A., Gray R., Giantonio B., O'Dwyer P., Comis R. L., Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology group portfolio of clinical trials Clinical Cancer Research 2004 10 4 1206 1211 (Pubitemid 38365208)
108. Kulke M. H., Stuart K., Enzinger P. C., Ryan D. P., Clark J. W., Muzikansky A., Vincitore M., Michelini A., Fuchs C. S., Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors Journal of Clinical Oncology 2006 24 3 401 406 (Pubitemid 46630459)
109. Choi H. J., Song B. J., Gong Y. D., Gwak W. J., Soh Y., Rapid degradation of hypoxia-inducible factor-1 by KRH102053, a new activator of prolyl hydroxylase 2 British Journal of Pharmacology 2008 154 1 114 125 (Pubitemid 351620399)
110. Temes E., Martn-Puig S., Acosta-Iborra B., Castellanos M. C., Feijoo-Cuaresma M., Olmos G., Aragonés J., Landazuri M. O., Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase Journal of Biological Chemistry 2005 280 25 24238 24244 (Pubitemid 40884913)